Flputnam Investment Management Co. Makes New Investment in Genelux Corporation $GNLX

Flputnam Investment Management Co. bought a new stake in Genelux Corporation (NASDAQ:GNLX) in the second quarter, HoldingsChannel.com reports. The fund bought 231,405 shares of the company’s stock, valued at approximately $697,000.

Several other institutional investors also recently made changes to their positions in the stock. Global Retirement Partners LLC acquired a new stake in shares of Genelux during the 2nd quarter worth approximately $686,000. Goldman Sachs Group Inc. lifted its holdings in shares of Genelux by 451.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 183,807 shares of the company’s stock worth $801,000 after purchasing an additional 150,463 shares during the last quarter. 683 Capital Management LLC acquired a new position in Genelux during the 4th quarter valued at approximately $572,000. Marshall Wace LLP boosted its position in Genelux by 312.3% during the 4th quarter. Marshall Wace LLP now owns 139,148 shares of the company’s stock valued at $607,000 after purchasing an additional 105,402 shares during the period. Finally, Millennium Management LLC bought a new position in Genelux during the 4th quarter worth $455,000. 37.33% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wall Street Zen lowered Genelux from a “sell” rating to a “strong sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a report on Friday, July 17th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Genelux Trading Down 1.5%

NASDAQ GNLX opened at $2.70 on Tuesday. Genelux Corporation has a 52 week low of $2.29 and a 52 week high of $8.53. The stock has a market cap of $121.07 million, a price-to-earnings ratio of -3.14 and a beta of 0.60. The company has a 50-day moving average price of $2.89 and a two-hundred day moving average price of $2.77.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). As a group, equities research analysts expect that Genelux Corporation will post -0.8 earnings per share for the current fiscal year.

Insider Activity at Genelux

In other Genelux news, Director John Thomas sold 10,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $2.98, for a total transaction of $29,800.00. Following the completion of the transaction, the director owned 472,784 shares in the company, valued at approximately $1,408,896.32. The trade was a 2.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John W. Smither sold 12,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $2.91, for a total value of $34,920.00. Following the transaction, the director owned 91,403 shares of the company’s stock, valued at $265,982.73. This trade represents a 11.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 25,868 shares of company stock worth $76,120. 7.50% of the stock is owned by insiders.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.